Page last updated: 2024-12-08

n-acetyl-n-formyl-5-methoxykynurenamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyl-N-formyl-5-methoxykynurenamine: metabolite of melatonin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID171161
CHEMBL ID1882218
CHEBI ID194285
SCHEMBL ID8939336
MeSH IDM0123196

Synonyms (39)

Synonym
n1-acetyl-n2-formyl-5-methoxykynuramine
n-acetyl-n-formyl-5-methoxykynuramine
n-acetyl-n-formyl-5-methoxykynurenamine
nsc-688263
NCI60_031860
afmk
C05642
formyl-n-acetyl-5-methoxykynurenamine
NCGC00165716-01
nsc688263
FT-0661243
n-gamma-acetyl-n-2-formyl-5-methoxykynurenamine
n-[3-(2-ormamido-5-methoxyphenyl)-3-oxopropyl]acetamide
CHEBI:194285
n-[3-(2-formamido-5-methoxyphenyl)-3-oxopropyl]acetamide
unii-s82p8jz4yj
52450-38-1
s82p8jz4yj ,
acetamide, n-(3-(2-(formylamino)-5-methoxyphenyl)-3-oxopropyl)-
nsc 688263
n-|a-acetyl-n-2-formyl-5-methoxykynurenamine
AB12510
SCHEMBL8939336
CHEMBL1882218
acetyl-n-formyl-5-methoxykynurenamine
n-(3-(2-(formylamino)-5-methoxyphenyl)-3-oxopropyl)-acetamide
DTXSID90200451
AKOS030240039
n-[3-(2-formamido-5-methoxy-phenyl)-3-oxo-propyl]acetamide
n-(3-(2-formamido-5-methoxyphenyl)-3-oxopropyl)acetamide
n-g-acetyl-n-2-formyl-5-methoxzykynurenamine
Q32039049
n-[3-[2-(formylamino)-5-methoxyphenyl]-3-oxypropyl]-acetamide
isosorbide2-mononitrate
SDCCGSBI-0633755.P001
MS-23729
HY-113314
n-?-acetyl-n-2-formyl-5-methoxykynurenamine
CS-0059577

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In the current review, we focus on melatonin metabolism which includes the synthetic rate-limiting enzymes, synthetic sites, potential regulatory mechanisms, bioavailability in humans, mechanisms of breakdown and functions of its metabolites."( One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?
Flores, LJ; Manchester, LC; Reiter, RJ; Tan, DX; Terron, MP, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" The inhibitory effects of AFMK on both DNA and lipid damage appear to be dose-response related."( N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant.
Burkhardt, S; Hardeland, R; Huo, YS; Kohen, R; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Shohami, E; Tan, DX, 2001
)
0.31
" Melatonin and AMK (10(-11)-10(-3) m), but not AFMK, inhibited nNOS activity in vitro in a dose-response manner."( Inhibition of neuronal nitric oxide synthase activity by N1-acetyl-5-methoxykynuramine, a brain metabolite of melatonin.
Acuña-Castroviejo, D; Camacho, E; Carrión, MD; Entrena, A; Escames, G; Espinosa, A; Gallo, MA; León, J; López, LC; Reiter, RJ; Rodríguez, MI; Tan, DX; Tapias, V, 2006
)
0.33
" granulata affects the antioxidant/pro-oxidant balance in a time and dosage dependent manner."( Effect of melatonin in the antioxidant defense system in the locomotor muscles of the estuarine crab Neohelice granulata (Decapoda, Brachyura).
Caldas, SS; Cruz, BP; Geihs, MA; Maciel, FE; Monserrat, JM; Nery, LE; Primel, EG; Vargas, MA, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Tryptophan Metabolism1855
superpathway of tryptophan utilization4292
superpathway of melatonin degradation526
melatonin degradation III17
Tryptophan metabolism2342

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase kappa isoform 1Homo sapiens (human)Potency21.19230.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Olfactory receptor 51E2Homo sapiens (human)EC50 (µMol)12.00000.00000.07800.5700AID1639697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
adenylate cyclase-activating G protein-coupled receptor signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
cell migrationOlfactory receptor 51E2Homo sapiens (human)
melanocyte differentiationOlfactory receptor 51E2Homo sapiens (human)
steroid hormone mediated signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
positive regulation of blood pressureOlfactory receptor 51E2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of smellOlfactory receptor 51E2Homo sapiens (human)
cellular response to fatty acidOlfactory receptor 51E2Homo sapiens (human)
melanocyte proliferationOlfactory receptor 51E2Homo sapiens (human)
positive regulation of renin secretion into blood streamOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nuclear steroid receptor activityOlfactory receptor 51E2Homo sapiens (human)
G protein-coupled receptor activityOlfactory receptor 51E2Homo sapiens (human)
olfactory receptor activityOlfactory receptor 51E2Homo sapiens (human)
signaling receptor activityOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
early endosome membraneOlfactory receptor 51E2Homo sapiens (human)
intracellular organelleOlfactory receptor 51E2Homo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1886283Displacement of 2-[125I]iodomelatonin from human melatonin MT2 receptor stably expressing in human HEK293 cell membranes upto 1 uM in presence of light-activated compounds by radioligand based competition binding assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Design and Validation of the First Family of Photo-Activatable Ligands for Melatonin Receptors.
AID1886282Displacement of 2-[125I]iodomelatonin from human melatonin MT2 receptor stably expressing in human HEK293 cell membranes upto 1 uM under dark condition by radioligand based competition binding assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Design and Validation of the First Family of Photo-Activatable Ligands for Melatonin Receptors.
AID1886272Displacement of 2-[125I]iodomelatonin from human melatonin MT1 receptor stably expressing in human HEK293 cell membranes upto 1 uM in presence of light-activated compounds by radioligand based competition binding assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Design and Validation of the First Family of Photo-Activatable Ligands for Melatonin Receptors.
AID1886278Displacement of 2-[125I]iodomelatonin from human melatonin MT1 receptor stably expressing in human HEK293 cell membranes upto 1 uM under dark condition by radioligand based competition binding assay2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Design and Validation of the First Family of Photo-Activatable Ligands for Melatonin Receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.82)18.7374
1990's1 (1.82)18.2507
2000's37 (67.27)29.6817
2010's12 (21.82)24.3611
2020's4 (7.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index6.53 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]